Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
16:00:52 EDT Sun 15 Mar 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:PHAR - PHARMING GROUP NV SPON ADS EACH REP 10 ORD SHS - https://www.pharmanetics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
PHAR - Q0.17.48·19.700.114.51-0.63-4.235.951229715.14  15.37  14.5021.30  7.501816:10:05Mar 1215 min RT 2¢

Recent Trades - Last 10 of 297
Time ETExPriceChangeVolume
16:10:05Q14.51-0.631
16:04:41Q14.51-0.631
16:00:05Q14.51-0.6323
16:00:05Q14.51-0.6380
16:00:05Q14.51-0.6338
16:00:05Q14.51-0.63100
16:00:05Q14.51-0.6318
16:00:05Q14.51-0.63100
16:00:05Q14.51-0.6312
16:00:00Q14.51-0.638

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-03-12 02:00U:PHARNews ReleasePharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow
2026-02-03 01:00U:PHARNews ReleasePharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day
2026-02-01 15:17U:PHARNews ReleasePharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja(TM) (leniolisib) in children aged 4 to 11 years with APDS
2026-01-08 01:00U:PHARNews ReleasePharming Group reports preliminary 2025 revenues and announces Investor Day
2025-11-06 01:00U:PHARNews ReleasePharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow
2025-10-20 02:01U:PHARNews ReleasePharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio
2025-10-06 11:36U:PHARNews ReleasePharming Group provides update on previously announced G&A expense reduction plan
2025-10-01 01:00U:PHARNews ReleasePharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years
2025-09-10 01:00U:PHARNews ReleasePharming Group promoted to the Euronext AMX(TM) index
2025-09-02 01:00U:PHARNews ReleasePharming Group appoints Kenneth Lynard as Chief Financial Officer
2025-07-31 01:00U:PHARNews ReleasePharming Group reports second quarter and first half 2025 financial results and provides business update
2025-06-24 01:00U:PHARNews ReleasePharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis
2025-05-08 01:00U:PHARNews ReleasePharming Group reports first quarter 2025 financial results and provides business update
2025-04-25 09:00U:PHARNews ReleasePharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS)
2025-04-23 03:30U:PHARNews ReleasePharming receives positive recommendation from NICE for Joenja(TM)▼(leniolisib) as a treatment for APDS
2025-03-20 02:00U:PHARNews ReleasePharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation